In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion

Executive Summary

The July 1 approval of Johnson & Johnson’s novel anticoagulant Xarelto for prevention of deep vein thrombosis is an important step for J&J and its ex-U.S. partner Bayer AG as they gear up to play in the highly promising but increasingly complicated world of novel anticoagulants.
Advertisement

Related Content

Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
Xarelto Filing Puts It Out Ahead In Venous Thromboembolism
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
Xarelto Faces Approval, Labeling Obstacles Even After Cmte. Endorsement
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors

Topics

Advertisement
UsernamePublicRestriction

Register

PS053569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel